|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-11-27
|
|
pubmed:abstractText |
(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy. This was followed by 4 cycles of the same chemotherapy as adjuvant therapy. (2) To determine preliminary estimates of the overall and disease-free survival associated with the use of this regimen. (3) To compare the toxicities and early survival results of patients treated with the current regimen to those of patients who completed our prior trial of concurrent chemoradiation infusion with 5-FU/LV chemotherapy and regional nodal and prophylactic hepatic irradiation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
pubmed-author:AbramsR ARA,
pubmed-author:CameronJ LJL,
pubmed-author:ChakravarthyAA,
pubmed-author:DonehowerR CRC,
pubmed-author:GrochowL BLB,
pubmed-author:HrubanR HRH,
pubmed-author:HurwitzHH,
pubmed-author:JaffeeE MEM,
pubmed-author:KormanL TLT,
pubmed-author:LillemoeK DKD,
pubmed-author:O'ReillySS,
pubmed-author:YeoC JCJ,
pubmed-author:ZahurekM LML
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1089-96
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11072167-Adenocarcinoma,
pubmed-meshheading:11072167-Adult,
pubmed-meshheading:11072167-Aged,
pubmed-meshheading:11072167-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11072167-Chemotherapy, Adjuvant,
pubmed-meshheading:11072167-Dipyridamole,
pubmed-meshheading:11072167-Disease-Free Survival,
pubmed-meshheading:11072167-Duodenal Neoplasms,
pubmed-meshheading:11072167-Female,
pubmed-meshheading:11072167-Fluorouracil,
pubmed-meshheading:11072167-Follow-Up Studies,
pubmed-meshheading:11072167-Humans,
pubmed-meshheading:11072167-Leucovorin,
pubmed-meshheading:11072167-Male,
pubmed-meshheading:11072167-Middle Aged,
pubmed-meshheading:11072167-Mitomycin,
pubmed-meshheading:11072167-Neoplasm Recurrence, Local,
pubmed-meshheading:11072167-Pancreatic Neoplasms,
pubmed-meshheading:11072167-Pancreaticoduodenectomy,
pubmed-meshheading:11072167-Radiotherapy, Adjuvant,
pubmed-meshheading:11072167-Radiotherapy Dosage,
pubmed-meshheading:11072167-Time Factors
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
|
|
pubmed:affiliation |
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
|
|
pubmed:publicationType |
Journal Article
|
